Cti Biopharma (CTIC) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CTIC Annual Balance Sheets →
The balance sheet data below highlights changes in Cti Biopharma's financial position over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2023)
(Dec 31 2022) (Sep 30 2022) (Jun 30 2022) (Mar 31 2022)
Assets
Cash & cash equivalent24.21
Short-term Investments, Total34.80
Cash & Short-term Investments58.00
Accounts receivable22.96
Inventories0.78
Other Current Assets0.00
Prepaid Expense And Other Assets Current3.71
Total Current Assets86.45
Equipment/Property/Plant Net0.00
Intangible Assets22.71
Other Assets, Noncurrent3.11
Total Assets112.27
Liabilities
Accounts Payable, Current AC2.03
Accrued Liabilities, Current AC16.31
Long-term Debt, Current Maturities LO48.08
Other Liabilities, Current1.81
Total Current Liabilities68.23
Long-term debt0.00
Total Long-term Debt0.00
Other liabilities, Noncurrent69.39
Long Term Debt Royalty Financing Obligation Noncurrent68.37
Total Liabilities137.62
Stockholders' Equity
Common Stock Value0.13
Additional Paid In Capital Common Stock2,506.86
Retained Earnings / Accumulated Deficit-2,532.33
Other Equity-0.01
Common Stockholder's Equity-25.35
Preferred Stockholder's Equity0.00
Total Stockholder's Equity-25.35
Liabilities & Stockholder's Equity112.27
4 historic quarters locked

Sign in to unlock the full Cti Biopharma balance sheet history.

About Cti Biopharma Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000891293-23-000015

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.